Table 2 Cerebrovascular stenosis with TKIs for leukemia

Coon et al. 2013 [10]

70F

CML

Bil MCA, Bil PCA, Rt intracranical ICA, Rt ACA

8 Years

Medication

Nilotinib

NR

Alshiekh et al. 2016 [11]

50 M

CML

Bil MCA

NR

Bypass

Nilotinib

6 Months

Ozaki et al. 2017 [12]

74 M

CML

Lt intracranial ICA, BA

2.5 Years

Medication → stent

Nilotinib

3 Months

Chen et al. 2018 [13]

49F

CML

Lt intracranial ICA

1 Year

stent

Nilotinib

1 Month (re-stenosis)

Suzuki et al. 2019 [14]

55 M

CML

Rt intracranial ICA, Lt MCA

3 Years

Bypass

Nilotinib

11 Months

Nakaya et al. 2019 [15]

76 M

CML

Bil cervical ICA

7 Years

Medication → CAS

Nilotinib

4 Months

Uemura et al. 2020 [16]

62 M

CML

Rt MCA, Lt ACA, Lt PCA

9 Years

Medication

Nilotinib

24 Months

59 M

CML

Lt MCA, BA

7.5 Years

Medication

Nilotinib

NR

Spina et al. 2020 [17]

62 M

CML

Bil cervical ICA

3 Months

Medication

Ponatinib

12 Months

Fujiwara et al. 2021 [4]

53F

CML

Bil cervical ICA, Bil subclavian A, Lt VA

5.5 Years

PTA

Nilotinib

42 Months

Hirayama et al. 2022 [3]

46F

CML

Bil cervical ICA

10 Years

CAS

Nilotinib

3 Months

43F

CML

Bil intracranial ICA

3 Months

Medication

Ponatinib

3 Months

Rai & Hara. 2023 [18]

39F

ALL

Rt MCA, cervical ICA

3.5 Years

Bypass

Nilotinib

6 Months

Present Case1

53 M

CML

Lt intracranial ICA

5 Years

Medication → Bypass

Ponatinib

12 Months

Present Case2

74 M

CML

Bil intracranial ICA, Bil MCA, Lt cervical ICA

6 Years

Bypass, CAS

Nilotinib

12 Months